TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06351423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest Bathing (FB)
Description: The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet
Description: The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
Study: NCT05808582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide，fulvestrant
Description: chidamide combined with fulvestrant
Study: NCT05134597

Intervention type: GENETIC
Intervention: Genetic assessment
Description: Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.

Intervention type: GENETIC
Intervention: Genetic assessment
Description: Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
Study: NCT04734977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT)
Description: High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
Study: NCT05588817

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PCR polymorphism
Description: PCR polymorphism in Rhomatoid arthritis patients in Egypt

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PCR polymorphism
Description: PCR polymorphism in Rhomatoid arthritis patients in Egypt
Study: NCT05990816

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood works for homocysteine levels
Description: In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
Study: NCT06389435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to undergo TKR or RTKR
Description: Total knee replacement (control group)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be randomized to undergo TKR or RTKR
Description: Total knee replacement (control group)
Study: NCT05631314

Intervention type: PROCEDURE
Intervention: operative treatment
Description: Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.

Intervention type: PROCEDURE
Intervention: non-operative treatment
Description: Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
Study: NCT04734977

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham high-intensity laser therapy (Sham HILT)
Description: Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
Study: NCT05490524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GATEKEEPER
Description: The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GATEKEEPER
Description: The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
Study: NCT04734977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Exercise
Description: As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study: NCT05214404

Intervention type: OTHER
Intervention: Patients diagnosed with ulcerative colitis
Description: Patients with ulcerative colitis diagnosed by endoscopy and histopathology
Study: NCT04299152

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator-Treated Mononuclear Cells Apheresis
Description: SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation.
Study: NCT05301621

Intervention type: OTHER
Intervention: Akcelerometry follow up
Description: The patients and control group will be followed up with single accelerometer.

Intervention type: OTHER
Intervention: Akcelerometry follow up
Description: The patients and control group will be followed up with single accelerometer.
Study: NCT04748679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Intervention
Description: The worry intervention is weekly individual therapy with a trained therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Befriending
Description: The worry intervention is weekly individual therapy with a trained therapist
Study: NCT05475028

Intervention type: OTHER
Intervention: RRBS
Description: Reduced Representation Bisulfite Sequencing

Intervention type: OTHER
Intervention: RRBS
Description: Reduced Representation Bisulfite Sequencing

Intervention type: OTHER
Intervention: RRBS
Description: Reduced Representation Bisulfite Sequencing
Study: NCT05245682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolinapant
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT05028699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack
Description: Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
Study: NCT06147362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-PEG2-RM26
Description: Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
Study: NCT05304598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: routine awake intubation as per current unit standard of care,
Study: NCT05307627

Intervention type: DRUG
Intervention: low-dose naltrexone
Description: LDN doses \<20 mg/day

Intervention type: DRUG
Intervention: low-dose naltrexone
Description: LDN doses \<20 mg/day

Intervention type: DRUG
Intervention: low-dose naltrexone
Description: LDN doses \<20 mg/day
Study: NCT05752240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia
Study: NCT06158282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary apnoea
Description: Walking apneas at high lung volume with cycles of 15-10s (apnea - breathing) during 6 minutes
Study: NCT06212843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric training
Description: The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional exercises
Description: The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats
Study: NCT05917275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 4 weeks of Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: 4 weeks of Olmesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 4 weeks of Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan
Description: 4 weeks of Amlodipine/Olmesartan
Study: NCT06265467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed Sinus Elevation
Description: using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Sinus Elevation
Description: using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
Study: NCT04899024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTI
Description: PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-Control
Description: Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
Study: NCT06043245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Switch
Description: Classic Duodenal Switch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SADI-S
Description: SADI-S with a 300cm common channel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minigastric Bypass
Description: Classic minigastric bypass
Study: NCT06017960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling + usual care
Description: Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling + usual care
Description: Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines.
Study: NCT05318040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS121
Description: CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS121
Description: CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS121
Description: CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS121
Description: CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided as visually matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided as visually matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided as visually matching placebo capsules.
Study: NCT04899024

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management for PrEP Adherence
Description: Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for PrEP Adherence
Description: Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
Study: NCT05613088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-202
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Specified dose on specified days
Study: NCT06161415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod eye drops
Description: n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod eye drops
Description: n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod eye drops
Description: n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod eye drops
Description: n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod eye drops
Description: n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
Study: NCT05695794

Intervention type: OTHER
Group type: OTHER
Intervention: the group with a bed head height of 45 degrees
Description: Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the group with a bed head height of 30 degrees
Description: Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
Study: NCT05441215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: nirmatrelvir/ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: nirmatrelvir/ritonavir
Study: NCT05848466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous
Study: NCT05766462

Intervention type: OTHER
Intervention: Pacemaker lower rate setting
Description: Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.
Study: NCT05848466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous
Study: NCT05509855

Intervention type: GENETIC
Intervention: Genetic: WU-CART-007
Description: No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy